Member Info for HelloSanDiego

Manifesto,

If there's a takeover any time soon it's most likely to be Polygon buying up the company at well under £1 a share, and I think the chances of a JV in the next 12 months is slim too.

If they're what you're pinning your hopes on, you might be better off just 'investing' in lottery tickets.

It's not only the $402m it could add to the bottom line that matters here.

The company's chances of getting one of its drugs to market has just increased by a further 50%. As soon as one succeeds it proves the company's tech actually works and the market cap gets well on its way to the tens of billions.

MrCosts - "Having L2 access makes absolutely no difference. "

Having more information means you know more. There's one important difference.

It's like I said to Patagucci yesterday, when significant news was expected the price consistently rose on Friday afternoons and fell back during the week. This happened most weeks in the run up to the P2 and P3 results.

An announcement we're on STRIVE would be equally transformative.

Patagucci - "After the rise on Friday I was expecting RNS this morning"

In the months leading up to the Phase 2 and 3 results, the price regularly rose on Fridays and dropped back midweek before rising again the following Friday afternoon.

With 2 non-trading days, the likelihood of a meaningful development in that 64-hour period is higher than in the 15-hour period during weekdays. That's what I'm putting it down to.

Patagucci - "2:1 buys to sells"

If you're basing that on what you see on this site's "Share Trades" tab, it's probably meaningless. The site seems to just estimate which trades are sells and which are buys by looking at whether the exeuction price is nearer to the bid or ask.

Andrewpcapp - "It's just like the old days on here today. "

And the price rising late on the Friday afternoon because there's a chance good news will land first thing Monday morning.

MrCosts - "Even with new funded trial, we will still need a fund raise to keep the light during the 2 years to complete trial and obtain results."

And we'll still be back on track to a $2-3bn market cap. So quit your whining.

A low volume day would normally be around 170k. The lowest I can find in the past six months is 150k, which probably makes it the lowest since January 2020.

We're currently on track for half that today. I think it's a sign of the complete uncertainty as to where this is heading. My personal feeling is that the next 2-3 months are make or break for shareholders here.

Viletrader - "Hasn't affected at all others juniors from the same sector"

Yes it has. There are around 50 small and mid-cap biotech stocks listed in the UK.

Around 8 are up, 16 haven't changed and 25 are down today.

EDIT: Actually I'm not sure exactly when the others were added. But it was definitely long after the DoQ vacancy.

I messaged the company early last week to ask if they had an ETA on the Director of Quality vacancy.

I didn't get a reply so on Thursday I emailed Consilium the same question. Still no reply, but the following day the advert was removed from the website and the other two roles were advertised. Draw your own conclusions, but I think it's a strong sign that they've got the nod from the STRIVE team. That's the reason I think things are looking good.

MrCosts,

It's a small company with a small team who all have confidence in each other, and who we all chose to back. The more you whine about the current situation, the more credibility you lose.

far preferable = more profitable

MrCosts - "Here we go, tide is turning already and people actually facing reality that another fund raise will be required."

I think it was me who brought up the topic of a fundraise earlier today when I said "If the directors already have confirmation we're on STRIVE, a fundraise late next year would be far preferable to a joint venture."

Titania,

The STRIVE selection criteria clearly explains how and why they choose to select certain drugs for inclusion. Joint ventures aren't one of the things they use to decide if a drug is worth testing.

Titania - "Why advance Scorpio-HR and not advance SNG001. Is that the real question we are asking?"

I'm not, because I've read the STRIVE selection criteria and can see why it would've taken priority over us.

Do you think maybe the reason is that, as we know, the ACTIV project got cancelled so there was nobody to analyse the data and write it up?

Manifesto - "A year...... I have made the point and backed it up."

I disagree. Can you suggest any reason why the ACTIV team would deliberately hold back vital data for a year?

Manifesto,

You must be aware of instances where trials have been stopped because the interim results are good enough. But that doesn't mean they have data that is fit for publication.